Inability to provide written informed consent
Known history of prior intracranial bleeding
On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in the prior 10 days
Known allergies to aspirin, ticagrelor or cangrelor
On treatment with oral anticoagulant
Treatment with glycoprotein IIb/IIIa inhibitors
Fibrinolytics within 24 hours
Active bleeding
High risk of bleeding
Known platelet count <80x106/mL
Known hemoglobin <10 g/dL
Intubated patients (prior to randomization)
Known creatinine clearance <30 mL/minute or on hemodialysis.
Known severe hepatic dysfunction
Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection
Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.
Pregnant or lactating females.

NCT03247738_exc_T2
Condition
intracranial bleeding
NCT03247738_exc_T3
Qualifier
prior
NCT03247738_exc_T4
Drug
P2Y12 receptor antagonist
NCT03247738_exc_T5
Drug
ticlopidine
NCT03247738_exc_T6
Drug
clopidogrel
NCT03247738_exc_T7
Drug
prasugrel
NCT03247738_exc_T8
Drug
ticagrelor
NCT03247738_exc_T9
Scope
ticlopidine, clopidogrel, prasugrel, ticagrelor
NCT03247738_exc_T10
Temporal
prior 10 days
NCT03247738_exc_T11
Condition
allergies
NCT03247738_exc_T12
Drug
aspirin
NCT03247738_exc_T13
Drug
ticagrelor
NCT03247738_exc_T14
Drug
cangrelor
NCT03247738_exc_T15
Scope
aspirin, ticagrelor or cangrelor
NCT03247738_exc_T16
Drug
anticoagulant
NCT03247738_exc_T17
Qualifier
oral
NCT03247738_exc_T18
Drug
glycoprotein IIb/IIIa inhibitors
NCT03247738_exc_T19
Procedure
Fibrinolytics
NCT03247738_exc_T20
Temporal
within 24 hours
NCT03247738_exc_T21
Condition
Active bleeding
NCT03247738_exc_T22
Qualifier
High risk
NCT03247738_exc_T23
Condition
bleeding
NCT03247738_exc_T24
Measurement
platelet count
NCT03247738_exc_T25
Value
<80x106/mL
NCT03247738_exc_T26
Measurement
hemoglobin
NCT03247738_exc_T27
Value
<10 g/dL
NCT03247738_exc_T28
Condition
Intubated
NCT03247738_exc_T29
Temporal
prior to randomization
NCT03247738_exc_T30
Reference_point
randomization
NCT03247738_exc_T31
Measurement
creatinine clearance
NCT03247738_exc_T32
Value
<30 mL/minute
NCT03247738_exc_T33
Procedure
hemodialysis
NCT03247738_exc_T34
Condition
hepatic dysfunction
NCT03247738_exc_T35
Qualifier
severe
NCT03247738_exc_T36
Condition
sick sinus syndrome
NCT03247738_exc_T37
Condition
SSS
NCT03247738_exc_T38
Condition
AV block
NCT03247738_exc_T39
Qualifier
high degree
NCT03247738_exc_T40
Procedure
pacemaker
NCT03247738_exc_T41
Negation
without
NCT03247738_exc_T42
Drug
drugs
NCT03247738_exc_T43
Condition
CYP3A4 metabolism
NCT03247738_exc_T44
Drug
ticagrelor
NCT03247738_exc_T45
Mood
interfering with
NCT03247738_exc_T46
Drug
Ketoconazole
NCT03247738_exc_T48
Drug
itraconazole
NCT03247738_exc_T49
Drug
voriconazole
NCT03247738_exc_T50
Drug
clarithromycin
NCT03247738_exc_T51
Drug
nefazodone
NCT03247738_exc_T52
Drug
ritonavir
NCT03247738_exc_T53
Drug
saquinavir
NCT03247738_exc_T54
Drug
nelfinavir
NCT03247738_exc_T55
Drug
indinavir
NCT03247738_exc_T56
Drug
atazanavir
NCT03247738_exc_T57
Drug
telithromizycin
NCT03247738_exc_T58
Scope
Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin
NCT03247738_exc_T59
Condition
Pregnant
NCT03247738_exc_T60
Condition
lactating
NCT03247738_exc_T61
Person
females
NCT03247738_exc_T62
Scope
Pregnant or lactating